The analysis revealed consistent gastrointestinal-related adverse events across all weight groups, including nausea, vomiting, decreased appetite, and weight loss
Glucagon-receptor agonism increases energy expenditure and hepatic fat mobilization, which is part of why retatrutide is so effective at reducing fat and liver fat
do not dispose of trial medicines through other routes without explicit authorisation from the trial team
This provides a clear view into how these therapies are being integrated into diabetes care at scale and highlights the value of Marketplace data for tracking treatment adoption and patient outcomes in real time (Figure 1)
GLP-1 receptor agonist medications like semaglutide injections, while generally well-tolerated, can cause side effects like nausea, vomiting, diarrhea, constipation, and abdominal pain in some people
Until then, our medically supervised weight loss programs include FDA-approved options with proven results and clinical oversight at every step